Published: July 31, 2018

Introduction {#sec1}
============

Follicular T helper (Tfh) cells are the effector T cell subset that is specialized in promoting the T cell-dependent B cell response and the germinal center (GC) reaction ([@bib8], [@bib37], [@bib46]). These cells express the BCL-6 transcription regulator ([@bib20], [@bib34], [@bib54]) and exhibit a unique CXCR5^hi^CCR7^lo^PD-1^+^ICOS^+^ surface phenotype. To develop into Tfh cells, naive T cells are initially activated in the T cell zone by dendritic cells ([@bib10], [@bib13]). Antigen activation not only causes upregulation of BCL-6, ICOS, and PD-1 but also leads to CXCR5 upregulation and CCR7 downregulation, which together guide activated T cells to relocate toward the T zone-follicle border (T-B border) and enter the follicle ([@bib45]). At the T-B border and particularly inside the follicle, T cells not only escape from high concentrations of IL-2 and IL-7 that inhibit BCL-6 expression ([@bib1], [@bib21], [@bib30], [@bib35]) but also experience IL-6 produced locally that helps to promote Tfh cell development and maintain the Tfh identity ([@bib17], [@bib33], [@bib37]).

Signaling through B7-family costimulatory molecules CD28 and ICOS is important for Tfh cell development. CD28 co-stimulates for T cell priming, whereas ICOS co-stimulation promotes the CXCR5 upregulation ([@bib7]). Moreover, in a costimulation-independent manner that requires ICOSL expression by follicular bystander B cells, ICOS signaling optimizes phosphoinositide-3 kinase (PI3K)-dependent pseudopod dynamics, promotes T cell persistent motility at the T-B border, and thereby enables CXCR5-expressing T cells to not only sense the CXCL13 gradient emanating from the follicle but also efficiently migrate across the border and into the follicle ([@bib52]). Constitutive ICOS signaling in the follicle is required for maintaining the follicular residence of T cells ([@bib49]). ICOS is important not only for follicular recruitment and maintenance of Tfh cells but also for help-delivering functions of Tfh cells. Tfh cells interact with antigen-specific B cells and provide help signals such as CD40L through cell-cell contacts. ICOS co-stimulates calcium fluxes in Tfh cells during antigen-specific interactions with GC B cells, promotes T-B contacts in the form of entanglement, and facilitate rapid selection of high-affinity B cells through the ICOS-CD40 intercellular positive feedback between the two types of cells ([@bib27]). Therefore, ICOS functions in both a costimulation-dependent and -independent manner to promote Tfh cell development and function. However, given that chemokine receptors signal to PI3K, and that CXCL13, which is amply available at the T-B border and in the follicle, could presumably activate PI3K in CXCR5-expressing T cells, it remains unresolved as to why ICOS is required for persistent T cell motility at the T-B border and in the follicle but not for migration in the T cell zone.

PD-1 is another B7-family molecule that, albeit inhibitory ([@bib23]), is highly expressed by Tfh cells, particularly those localized inside the GC territory ([@bib18]). For antigen-experienced CD8^+^ T cells, high expression of PD-1 is associated with functional exhaustion ([@bib2], [@bib50]). This is because the cytoplasmic domain of PD-1 contains an immunotyrosine-based inhibitory motif (ITIM) and an immunotyrosine-based switch motif (ITSM) and can recruit tyrosine phosphatases to dephosphorylate signaling components downstream of TCR and CD28 pathways ([@bib19], [@bib36], [@bib53]). In contrast, Tfh cells are highly functional and sensitive to antigen presented by cognate B cells. It is thought that the heightened PD-1 expression on Tfh cells simply reflects experience of antigen stimulation, especially when inside the GC, and Tfh cells have to function despite the PD-1-mediated inhibition. Alternatively, inhibitory functions of PD-1 might play a positive role in Tfh cell development and function.

In our search for a mechanistic explanation for the requirement of ICOS to promote T cell migration at the T-B border but not in the T cell-zone, we found that, in a cosignaling-independent manner, PD-1 suppressed PI3K activities triggered downstream of CXCR5. This inhibition was induced by PD-1 engagement by PD-L1 expressed on follicular bystander B cells. When unopposed by ICOS-mediated enhancement of PI3K activation, PD-1-mediated inhibition prevented follicular recruitment of activated T cells. Therefore, at the T-B border, PD-1 and PD-L1 favor follicular recruitment of those T cells expressing a high level of ICOS. By examining Tfh cells genetically impaired in PD-1 upregulation, we further found that PD-1 was also required for optimal GC localization of Tfh cells, for IL-21 production, and for setting a sufficiently stringent threshold for the GC B cell competition. Thus, by controlling both proper positioning and helper functions of Tfh cells, the inhibitory receptor PD-1 plays an essential role during the germinal center response.

Results {#sec2}
=======

PD-1 Suppresses PI3K Activation and Follicular T Cell Recruitment {#sec2.1}
-----------------------------------------------------------------

It has previously been shown that ICOS promotes PI3K-dependent T cell motility and is required to drive follicular T cell recruitment in a costimulation-independent manner ([@bib52]). Using the same quantitative *in vivo* homing assay as utilized in the previous study, we further verified that an intact p85-recruiting YxxM motif was required for ICOS-mediated promotion of follicular recruitment ([Figure S1](#mmc1){ref-type="supplementary-material"}). Because lymphocyte motility in general requires PI3K activities and because signaling of chemokine receptors such as CXCR5 activates PI3K, it is puzzling why ICOS is additionally required for motility and recruitment of activated T cells into the follicle, whereas ICOS is not necessary for T cell migration in the T cell zone ([@bib52]). Potentially, the follicular niche may contain factors that can inhibit T cell PI3K activities downstream of chemokine receptors such as CXCR5 and thereby impose a requirement for bystander ICOS signaling at the T-B border and in the follicle to boost and maintain PI3K activities and thereby promote T cell motility and recruitment. To test this hypothesis, we searched for surface-bound ligand-receptor pairs that meet the following three conditions. The receptor and ligand are expressed respectively by antigen-activated T cells and follicular parenchyma-constituting bystander B cells. Signaling through such receptors into T cells suppresses PI3K activities triggered by chemokine receptor CXCR5 and by ICOS. When this ligand or receptor is ablated, the requirement for ICOS to promote follicular migration may be relaxed.

Because PD-L1 is constitutively expressed by follicular B cells ([Figure 1](#fig1){ref-type="fig"}A), we first tested its effect on PI3K activation triggered by CXCR5 on T cells. To ensure a uniform response, T cells were retrovirally transduced with CXCR5 and PD-1 before being stimulated with CXCL13 in the presence of PD-L1-Fc fusion protein. As shown in [Figure 1](#fig1){ref-type="fig"}B, engagement of PD-1 by PD-L1-Fc protein significantly reduced CXCL13-triggered PI3K activities as measured by Akt phosphorylation. Consistent with this PI3K suppression, CXCL13-induced T cell polarization, which is a prerequisite for cell motility, was impaired when PD-1 was engaged by PD-L1-Fc ([Figure S2](#mmc1){ref-type="supplementary-material"}). PD-L1-Fc treatment also inhibited ICOS-stimulated PI3K activities ([Figure 1](#fig1){ref-type="fig"}C). To test whether PD-1 can inhibit CXCR5-driven follicular migration, localization of CXCR5-, PD-1-transduced T cells ([Figure 1](#fig1){ref-type="fig"}D) were examined 24 hr after being transferred into naive, unimmunized mice. As shown in [Figure 1](#fig1){ref-type="fig"}E, significantly fewer PD-1-overexpressing T cells migrated into the follicle despite enforced CXCR5 expression, resulting in a reduced homing coefficient ([Figure S3](#mmc1){ref-type="supplementary-material"}A).Figure 1Costimulation-Independent Suppression of PI3K Activities and Follicular Recruitment of T Cells by PD-1(A) Surface staining of PD-L1 or PD-L2 expression on follicular B cells. Grey histograms: isotype control staining.(B) CD4^+^ T cells retrovirally co-transduced with CXCR5 and PD-1 were starved in serum-free media for 3 hr. AKT phosphorylation was probed after 30 min CXCL13 stimulation at indicated concentrations in the presence or absence of PD-L1-Fc crosslinked by anti-human IgG. Data represent two independent experiments.(C) AKT phosphorylation was probed after CD4^+^ T cells were starved in serum-free media for 3 hr and then stimulated with anti-ICOS in the presence or absence of PD-L1-Fc at indicated concentration for 30 min. Data represent two independent experiments.(D) Splenic distribution patterns of CD4^+^ T cells retrovirally co-transduced with a combination of CXCR5 or control GFP and PD-1 or control RFP 24 hr after being injected into B6 mice (2--3 × 10^6^ sorted transduced cells per mouse).(E) Scatterplots of the homing coefficients of the four groups in (D), with each symbol indicating one section.Data are pooled from four independent experiments, with each experiment contributing 10--20 sections. Scale bar, 50 μm. ^∗∗^p \< 0.01; ns, not significant.

Endogenous PD-1 Antagonizes ICOS and Limits Follicular Recruitment in the Bystander Mode {#sec2.2}
----------------------------------------------------------------------------------------

CD4^+^ T cells upregulate PD-1 expression very soon after antigen stimulation ([@bib6], [@bib23]). To test whether endogenously expressed PD-1 suppresses follicular T cell recruitment and, if so, whether such suppression underlies the requirement for bystander ICOS-ICOSL interactions for recruitment, we resorted to a PD-1 knock-in strain in which an AP-1-binding site in the *Pdcd1* promoter is disabled so that T cells homozygous for this mutation (*Pdcd1*^KI/KI^) cannot upregulate PD-1 ([Figure S4](#mmc1){ref-type="supplementary-material"}; [@bib51]). As exemplified in [Figure 2](#fig2){ref-type="fig"}A and quantitated in [Figure 2](#fig2){ref-type="fig"}B, whereas CXCR5-transduced *Pdcd1*^+/+^ T cells efficiently migrated into follicles of normal B6 mice but failed to do so in *Icosl*^−/−^ mice, as expected according to previous observations ([@bib52]), *Pdcd1*^KI/KI^ T cells were indeed able to migrate into follicles composed of not only wild-type but also *Icosl*^−/−^ bystander B cells ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Furthermore, as compared to *Icos*^−/−^ T cells, *Pdcd1*^KI/KI^*Icos*^−/−^ T cells exhibited a significantly improved ability to migrate into normal follicles ([Figures 2](#fig2){ref-type="fig"}C, 2D, and [S3](#mmc1){ref-type="supplementary-material"}C). Importantly, because all the recipient mice used in these experiments were not immunized and transferred T cells are not stimulated by antigen *in vivo*, the inhibitory PD-1 effect on follicular T cell recruitment is likely based on triggering of PD-1 in a bystander mode by the ensemble of follicular B cells.Figure 2PD-1 Abrogation on Activated T Cells Rescues Follicular Homing Defect due to ICOSL-ICOS Deficiency(A and B) CXCR5- or GFP-transduced wild-type (top) or *Pdcd1*^KI/KI^ (bottom) CD4^+^ T cells were transferred into *Icosl*^*+/+*^ (left) or *Icosl*^*−/−*^ (right) mice (2--3 × 10^6^ cells per mouse). Representative splenic distribution patterns (A) and homing coefficients (B) of T cells 24 hr after adoptive transfer.(C and D) Representative splenic distribution patterns (C) and homing coefficients (D) of CXCR5-transduced *Icos*^+/+^, *Icos*^−/−^, or *Pdcd1*^KI/KI^*Icos*^−/−^ CD4^+^ T cells 24 hr after being adoptive transfer into B6 mice.Each symbol denotes one section. Data are pooled from five (B) or three (D) independent experiments. Scale bar, 100 μm. ^∗∗^p \< 0.01; ^∗∗∗∗^p \< 0.0001; ns, not significant.

To validate the bystander mode of PD-1 activation in the follicle, by a CRISPR/Cas9 strategy we created a PD-L1 (encoded by *Cd274*)-deleted strain ([Figure S5](#mmc1){ref-type="supplementary-material"}). We then made *Cd274*^−/−^:μMT 20:80 bone-marrow (BM) chimera in which 80% BM cells are from the μMT background that cannot produce B cells and 20% BM cells are of the *Cd274*^−/−^ genotype. Therefore, in such chimeras PD-L1 is absent from all follicular B cells while other hematopoietic cells are largely normal. When CXCR5-transduced *Icos*^−/−^ T cells were transferred into control *Cd274*^+/+^:μMT chimera, they failed to migrate into the follicle as efficiently as their wild-type counterpart T cells ([Figure 3](#fig3){ref-type="fig"}). However, this defect was significantly rescued in the *Cd274*^−/−^:μMT chimera ([Figures 3](#fig3){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}D). These data demonstrate that PD-1-mediated suppression of follicular recruitment is indeed mediated by PD-L1 expressed on bystander follicular B cells.Figure 3PD-L1 on Bystander B Cells Suppresses T Cell RecruitmentSplenic distribution patterns (A) and homing coefficients (B) of CXCR5-transduced *Icos*^+/+^ (top) or *Icos*^−/−^ (bottom) T cells 24 hr after adoptive transfer into mixed bone-marrow chimeric hosts of indicated types (2--3 × 10^6^ cells per mouse). Each symbol denotes one tissue section. Data are pooled from three experiments. Scale bar, 50 μm. ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001; ns, not significant.

Bystander PD-1 Triggering Inhibits Follicular T Cell Recruitment via Its ITSM and Activates SHP-2 {#sec2.3}
-------------------------------------------------------------------------------------------------

In the cytoplasmic domain of the PD-1 molecule, there are two inhibitory signaling motifs: Y225-based ITIM motif and Y248-based ITSM motif. When PD-1 functions as a co-inhibitory receptor to dampen TCR signaling, its ITSM plays the dominant role and mediates SHP-2 activation and recruitment ([@bib5], [@bib42]). To test whether bystander activation of PD-1 signals through ITIM or ITSM when inhibiting the follicular T cell recruitment, we compared Y225F mutant and Y248F mutant form of PD-1 molecules in the homing assay. As shown in [Figure 4](#fig4){ref-type="fig"}A and quantitated in [Figure 4](#fig4){ref-type="fig"}B, whereas the PD-1^Y225F^ mutant molecule was as inhibitory as the wild-type PD-1 molecule, PD-1^Y248F^ mutant lost the ability to suppress follicular T cell recruitment, indicating that ITSM also predominantly mediates PD-1 signaling activated in the bystander mode ([Figure S3](#mmc1){ref-type="supplementary-material"}E). When activated T cells were stimulated *in vitro* by PD-L1-Fc, we also detected an increase in SHP2 phosphorylation, which was not affected by concomitant ICOS stimulation ([Figure 4](#fig4){ref-type="fig"}C). It is therefore likely that SHP2 plays a role in mediating bystander PD-1 signaling as well.Figure 4PD-1-Mediated Suppression of Follicular T Cell Recruitment Implicates ITSM and SHP-2(A) Splenic distribution patterns of CD4^+^ T cells that were co-transduced with a vector expressing CXCR5 and another vector expressing control RFP (top left) or wild-type PD-1 (top right) or ITIM-mutated PD-1^Y225F^ (bottom left) or ITSM-mutated PD-1Y^248F^ (bottom right) 24 hr after being transferred into B6 recipients (2--3 × 10^6^ per mouse).(B) Scatterplots of homing coefficients of the four groups in (A). Each symbol denotes one tissue section. Data are pooled from three experiments. Scale bar, 100 μm. ^∗∗∗∗^p \< 0.0001; ns, not significant.(C) SHP-2 phosphorylation in CD4^+^ T cells after 30 min anti-ICOS stimulation in the presence or absence of PD-L1-Fc. Cells were pre-starved for 3 hr. Data represent two independent experiments.

PD-1 Suppresses Overall Tfh Cell Development {#sec2.4}
--------------------------------------------

Although the foregoing observations reveal a bystander mode of PD-1 functions and explains why bystander ICOS activation is required to promote follicular T cell recruitment, it remains paradoxical why Tfh cells must express a high level of PD-1 molecules. Consistent with previous findings of a negative role for the PD-1-PD-L1 molecular pair in humoral immunity ([@bib16]), PD-1-overexpressing T cells exhibited a ∼50% reduction in Tfh cell development, as measured by the frequency of CXCR5^hi^ or CXCR5^hi^Bcl-6^hi^ cells ([Figure S6](#mmc1){ref-type="supplementary-material"}A) or by the ratio between the follicular T cell density and their density in the T cell zone ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Combined with a ∼70% reduction in T cell expansion ([Figure S6](#mmc1){ref-type="supplementary-material"}A), the absolute number of Tfh cells would be reduced to 10%--15% of the normal level. Conversely, when *Pdcd1*^KI/KI^ T cells that could not upregulate PD-1 were activated *in vivo* after antigen immunization, there was a 2- to 3-fold increase in Tfh cell development as measured by the frequency of CXCR5^hi^ or CXCR5^hi^Bcl-6^hi^ cells ([Figure S6](#mmc1){ref-type="supplementary-material"}C) or by the differential distribution between the follicle and the T cell zone ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Combined with a ∼3-fold increase in T cell expansion ([Figure S6](#mmc1){ref-type="supplementary-material"}C), there was typically a 6- to 10-fold increase in the absolute number of Tfh cells. Therefore, by these criteria widely used in the literature to evaluate Tfh cell development, PD-1 is arguably one of the most potent suppressors of Tfh cell development.

Bystander Engagement of PD-1 Helps Tfh Cell Concentration in GCs {#sec2.5}
----------------------------------------------------------------

To resolve this conceptual paradox, we tested the possibility that heightened PD-1 expression actually serves positive functions for Tfh cells. First, we confirmed previous findings that PD-1 was required for optimal IL-21 production by Tfh cells ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7C; [@bib14], [@bib22]). Next, given that Tfh cells must be concentrated in GCs in order to properly function as B cell helpers and that PD-1 is mainly a marker for GC-resident Tfh cells ([@bib18]), we considered the possibility that heightened PD-1 expression could help concentrate T cells into GCs. This is because when the overall chemo-sensing program of CXCR5^+^CCR7^lo^S1PR2^+^ Tfh cells favors localization to the follicular center, PD-1-mediated motility inhibition due to bystander PD-L1 engagement in the follicular mantle could push these cells into the GC. To test this scenario, we transferred wild-type MD4 B cells that recognize hen egg lysozyme (HEL) and *Pdcd1*^KI/KI^ or wild-type OT-II T cells that recognize ovalbumin(OVA)~323-339~ presented on the I-A^b^ molecule into B6 mice. Following HEL-OVA immunization, we examined the distribution of OT-II Tfh cells in GCs and the follicular area. Consistent with a PD-1-mediated concentrating effect, we indeed observed a decrease in the density ratio between the GC and the follicle for *Pdcd1*^KI/KI^ Tfh cells as compared to that for their wild-type counterparts ([Figures 5](#fig5){ref-type="fig"}A and 5B). We also examined the distribution of wild-type and *Pdcd1*^KI/KI^ Tfh cells in wild-type MD4 GCs developed in PD-L1-sufficient or -deficient mice. As exemplified in [Figure 5](#fig5){ref-type="fig"}C and quantitated in [Figure 5](#fig5){ref-type="fig"}D, loss of either PD-1 on Tfh cells or PD-L1 on follicular bystander B cells significantly reduced the Tfh cell density in GCs in comparison to that in the follicle. These data suggest that PD-1 and PD-L1 serve to concentrate Tfh cells into the GC from the follicle.Figure 5PD-1 and PD-L1 Promote Tfh Cell Concentration toward the GC Area(A and B) GFP-transduced wild-type or *Pdcd1*^KI/KI^ OT-II T cells were transferred into B6 mice (5 × 10^5^ sorted GFP^+^ cells per mouse) together with 5 × 10^5^ dsRed-expressing MD4 B cells. OT-II distribution patterns (A) and density ratios between the GCs and the follicle (B) in draining lymph nodes 5 days after subcutaneous HEL-OVA immunization.(C and D) Wild-type or *Cd274*^−/−^ mice received 5 × 10^5^ GFP-transduced wild-type or *Pdcd1*^KI/KI^ OT-II T cells together with 5 × 10^5^ dsRed-expressing MD4 B cells. OT-II distribution patterns (C) and density ratios between the GCs and the follicle (D) in draining lymph nodes 5 days after subcutaneous HEL-OVA immunization.Scale bar, 100 μm. All data are pooled from three independent experiments involving 3--4 mice per condition per experiment. ^∗∗∗∗^p \< 0.0001; ns, not significant.

PD-1 Concentrates T Cells to GCs by Limiting CXCR3 Distraction {#sec2.6}
--------------------------------------------------------------

While PD-1 can optimize follicle-to-GC partitioning of Tfh cells by directly suppressing follicular migration in a bystander mode, its signals may also change intrinsic properties of Tfh cells to optimize their GC positioning indirectly. To probe this issue, we co-transferred MD4 B cells and wild-type or *Pdcd1*^KI/KI^ OT-II cells into separate B6 mice, immunized these mice with HEL-OVA, and isolated two types of Tfh cells after MD4 GCs developed for transcriptome analysis by RNA-seq. Using p~adj~ \< 0.01 as the cutoff, we observed only a few genes differentially expressed by CXCR5^hi^ Tfh cells of the two genotypes ([Figure 6](#fig6){ref-type="fig"}A; see [Table S1](#mmc2){ref-type="supplementary-material"} for a full list), including *Pdcd1* and *Cxcr3*. CXCR3, expressed by T cells after TCR stimulation ([@bib32]), is the receptor for chemokine CXCL9 and CXCL10 that are highly expressed in interfollicular regions immediately outside of follicles ([@bib15]). Responsiveness to CXCL9 or CXCL10 is not conducive to GC localization and incompatible with a Tfh cell phenotype ([@bib4]). Consistent with a requirement for PD-1 to dampen CXCR3 expression to limit potential distraction of Tfh cells by CXCL9 and/or CXCL10, we found heightened CXCR3 expression by *Pdcd1*^KI/KI^ Tfh cells as compared to wild-type Tfh cells ([Figure 6](#fig6){ref-type="fig"}B). To test whether CXCR3 can indeed distract Tfh cells from GC localization, we targeted CXCR3 by two separate shRNAs ([Figure 6](#fig6){ref-type="fig"}C). As exemplified in [Figure 6](#fig6){ref-type="fig"}D and quantitated in [Figure 6](#fig6){ref-type="fig"}E, these two independent CXCR3-targeting shRNAs were both able to significantly improve the follicle-to-GC partitioning for both the wild-type and *Pdcd1*^KI/KI^ Tfh cells. Together, these data indicate that a positive function of PD-1 expression is to restrict CXCR3-mediated distraction and promote Tfh cell concentration in the GC region.Figure 6PD-1 Restricts CXCR3 Expression and Promotes Confinement of Tfh Cells in GCs(A and B) GFP-transduced wild-type or *Pdcd1*^KI/KI^ OT-II T cells were transferred into B6 mice (5 × 10^5^ sorted GFP^+^ cells per mouse) together with 5 × 10^5^ dsRed-expressing MD4 B cells, and the recipients were subcutaneously immunized with HEL-OVA.(A) CXCR5^hi^ OT-II T cells were sorted from the two groups on day 5 and subjected to transcriptomic analysis by RNA-seq. Shown is unsupervised clustering of genes differentially expressed as defined by an adjusted p value \< 0.01.(B) CXCR3 expression on CXCR5^hi^ wild-type and *Pdcd1*^KI/KI^ OT-II T cells. Left, CXCR5^hi^ gate; middle, histograms; right, representative CXCR3 histogram overlay and MFI values of CXCR5^hi^ OT-II cells in three mice; data representative of three independent experiments; ^∗^p \< 0.05.(C) CXCR3 expression on CXCR5^hi^*Pdcd1*^KI/KI^ OT-II T cells that were transduced with scramble control shRNA or two separate CXCR3-targeting shRNAs. Grey histogram, isotype control.(D and E) Wild-type (left) or *Pdcd1*^KI/KI^ (right) OT-II T cells were transduced with scramble control shRNA or CXCR3-targeting shRNA and then were transferred into B6 mice (5 × 10^5^ Ametrine^+^ transduced cells per mouse) together with 5 × 10^5^ dsRed-expressing MD4 B cells. OT-II distribution patterns (D) and density ratios between the GCs and the follicle (E) in draining lymph nodes 5 days after subcutaneous HEL-OVA immunization.Scale bar, 100 μm. Each symbol denotes one tissue section. Data are pooled from three experiments involving three and four mice per condition per experiment. ns, not significant; ^∗^p \< 0.05; ^∗∗∗∗^p \< 0.0001.

PD-1 Maintains the Stringency of GC Selection {#sec2.7}
---------------------------------------------

Another aspect of GC biology that PD-1 on Tfh cells may regulate in a positive manner is affinity selection. When functioning as a co-inhibitory receptor engaged by its ligands on antigen-presenting cells, PD-1 can dampen TCR signaling ([@bib53], [@bib56]) and thereby reduce the ligand sensitivity of Tfh cells, a condition that should increase the overall stringency of selection in GCs ([@bib47]). To test this hypothesis, we first validated that, as would be predicted by the overall increase in *Pdcd1*^KI/KI^ Tfh cell development ([Figure S6](#mmc1){ref-type="supplementary-material"}), selective removal of PD-1 from adoptively transferred OT-II T cells would exaggerate the GC response following NP-OVA immunization in *Sap*^−/−^ mice ([Figures S7](#mmc1){ref-type="supplementary-material"}D and S7E), which cannot endogenously generate competent Tfh cells ([@bib38], [@bib55]). Of note, total plasma cells were also increased at the peak of the immune response. More importantly, the NP-binding fraction in GCs was significantly reduced in the *Pdcd1*^KI/KI^ OT-II group following NP-OVA immunization ([Figures S7](#mmc1){ref-type="supplementary-material"}D and S7E), implying a reduced stringency of GC selection and outgrowth of low-affinity or irrelevant specificities ([@bib26]).

Next, we constructed 1:1 BM chimera using CD45.1 mixed with *Cd274*^−/−^ CD45.2 BM cells or CD45.1 mixed with *Cd274*^+/+^ CD45.2 BM cells. As shown in [Figures 7](#fig7){ref-type="fig"}A and 7B, at day 8, 13, and 21 after NP-KLH immunization, *Cd274*^−/−^ B cells dominated the GC, the memory (except for day 21), and the splenic plasma cell compartments. PD-L1-deficient B cells also tended to dominate the BM plasma cell compartment as measured on day 21. These data suggest that the absence of PD-L1 allowed individual B cells to acquire more T cell help. On the other hand, PD-L1-deficient B cells were outcompeted by wild-type CD45.1 cells within NP-binding GC B cells ([Figures 7](#fig7){ref-type="fig"}A and 7B), suggestive of lower NP-binding affinities of PD-L1-deficient B cells and/or outgrowth of irrelevant antigen specificities. To directly examine the frequency of high-affinity cells within the mixed GCs, we sorted NP-binding GC B cells and sequenced the canonical V~H~186.2 gene segment. As shown in [Figure 7](#fig7){ref-type="fig"}C, PD-L1-deficient B cells harbored significantly fewer affinity-improving W33L mutation, despite a similar overall frequency of mutation. Together, these data indicate that PD-1 and PD-L1 interactions between Tfh and GC B cells help to maintain the stringency of affinity-based selection.Figure 7Compromised Affinity Maturation in the Absence of PD-1-PD-L1 Interactions between GC Tfh and B CellsMixed BM chimeras were constructed using 50% CD45.2 *Cd274*^+/+^ or *Cd274*^−/−^ BM cells and 50% CD45.1 BM cells. Chimeric mice were immunized with NP-KLH.(A) Gating strategies for total B cells, plasma cells, GC B cells, NP-specific GC B cells, and memory B cells (top row) and for CD45.1 and CD45.2 cells within each indicated population (bottom row). The example is from *Cd274*^−/−^:CD45.1 chimera.(B) Scatterplots of competitive competencies of CD45.2 cells in the two sets of mixed chimeras contributing to GC B cells, NP-specific GC B cells, NP-specific memory B cells and plasma cells, and BM plasma cells at day 8, day 13, or day 21 after immunization. The competitive competency is defined as the CD45.2/CD45.1 ratio in the indicated compartment normalized against the same ratio in the total B cell compartment or the GC compartment in the case of NP-specific GC cells. Data are pooled from three independent experiments involving 3--4 mice per group per experiment. Each symbol denotes one mouse. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ^∗∗∗∗^p \< 0.0001; ns, not significant.(C) Total mutation rates and frequencies of affinity-enhancing W33L mutation in NP-specific, V~H~186.2-carrying GC B cells isolated on day 13 after NP-KLH immunization. Numbers in the center of the pie chart indicate total numbers of clones analyzed, and numbers of W33L^+^ or W33L^−^ cells are indicated. Numbers of total mutation are presented as mean ± SEM. Frequencies of W33L mutations were compared by the Fisher's exact test. Data are pooled from three independent experiments, each involving 3--4 mice for each group.

Discussion {#sec3}
==========

This study uncovers a bystander mode of PD-1 function in suppressing the follicular recruitment of activated helper T cells. It is based on PD-1 engagement by PD-L1 constitutively expressed on follicular naive B cells. This is reminiscent of previous findings that ICOS functions in a bystander mode to optimize T cell motility and to promote follicular recruitment of activated helper T cells ([@bib52]). Given heightened CXCR5 expression on Tfh cells, CXCL13 in the follicle could be sufficient in driving their PI3K activation and motility, if not because of the inhibitory PD-L1 field. Indeed, the PD-1-mediated inhibition is likely the main reason why bystander ICOS activation is required for optimal T cell recruitment. Noticeably, the follicular homing defect of ICOS-deficient T cells is only partially rescued by abrogation of bystander PD-1-PD-L1 interactions, suggesting that additional inhibitory pathways may be in play to suppress follicular recruitment.

It is striking that both ICOS and PD-1 can function independently of TCR stimulation, that both regulate PI3K activities, and that ligands of both receptors are constitutively expressed by follicular bystander B cells. There is also evidence that CTLA-4, another B7-family molecule, may directly influence T cell adhesion and migration ([@bib40]). Possibly, in addition to their classical functions of co-signaling with the TCR, all B7-family molecules may possess an ability to directly regulate T cell motility and positioning in different settings *in vivo*.

A benefit of PD-1-mediated inhibition of follicular recruitment would be to ensure cells that actually move and dwell in the follicle are those that highly express ICOS. At the same time, because ICOS costimulation also promotes PD-1 upregulation ([@bib23]), TCR triggering and ICOS costimulation by cognate B cells in the follicle would promote and maintain PD-1 expression on Tfh cells. As a result, follicle-resident T cells could be locked in an ICOS^hi^PD-1^hi^ state. An ICOS^hi^PD-1^hi^ state is important for specific helper functions of Tfh cells. First, both ICOS and PD-1 promote IL-21 production from T cells. ICOS has been shown to induce c-Maf and IL-21 expression in both Tfh and Th17 cells ([@bib3]). With this study included, PD-1 has been shown in three independent systems as required for optimal IL-21 production from Tfh cells, providing one probable reason for why Tfh cells need to express high levels of PD-1 and be in the ICOS^hi^PD-1^hi^ state. However, given the general antagonistic relationship between ICOS and PD-1 signaling, future studies will have to delineate how exactly PD-1 promotes IL-21 production. Second, by restricting CXCR3 expression and suppressing potential distraction from CXCL9 and/or CXCL10, PD-1 helps to concentrate Tfh cells in GCs. The fact that some Tfh cells still express CXCR3 is consistent with previous findings that these cells are in a dynamic flux between GCs and follicles with a potential to escape the follicular area entirely ([@bib29], [@bib38], [@bib43], [@bib44]). Finally, in the dynamic GC environment, the ICOS-ICOSL pair promote affinity maturation by establishing an intercellular positive-feedback loop between Tfh and GC B cells, ensuring that high-affinity mutants that stochastically arise can be rapidly selected by T cells ([@bib27]). PD-1 can reduce the TCR ligand sensitivity ([@bib53]) and thereby enforce a more stringent selection threshold for competing B cells to also promote affinity maturation. On the other hand, PD-1 and PD-L1 have been reported to stabilize the immunological synapse between CD8 T cells and viral antigen-presenting cells during chronic viral infection ([@bib56]). This cell type-specific complexity of PD-1 functions requires further mechanistic clarification. When PD-1, PD-L2, or PD-L1 together with PD-L2 were ablated from the germline, these knockout animals exhibited reduction in GC and NP-specific plasma cells and increase in serum antibody affinities after NP-CGG immunization ([@bib14]). Given that non-Tfh cells including follicular T regulatory cells and B cells can express PD-1 and that PD-1 has a more general role in maintaining peripheral tolerance ([@bib23], [@bib39]), more complex physiology beyond Tfh-GC B cell interactions is probably also involved in producing those phenotypes.

Our study also highlights the importance of follicular bystander B cells, which have not been routinely considered as a relevant player in studies of cellular and molecular mechanisms regulating the Tfh cell development and germinal center reaction. Because bystander B cells that do not present antigen to Tfh cells are numerically dominant in the follicle even during active GC responses, their ensemble constitutes a niche that Tfh cells by definition cannot escape, and these T cells are constantly subjected to bystander triggering of ICOS, PD-1, and possibly additional receptors that would otherwise modulate TCR signaling in the context of cognate interactions between Tfh cells and antigen-specific B cells. From the perspective of niche regulation of motility and T cell recruitment, it is notable that many non-hematopoietic tissue cells can express PD-L1 under the influence of inflammatory cytokines such as interferons ([@bib11], [@bib41]) and that many types of tumors and tumor-associated macrophages can densely express PD-L1 ([@bib12], [@bib25]). We speculate that inhibitory effects of PD-1 on T cell migration may also be involved in regulating T cell infiltration into those inflammatory tissues and tumor niches.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**CD185 (CXCR5) Biotin (Clone REA215)Miltenyi BiotecCat\#130-102-057; RRID: [AB_2655798](nif-antibody:AB_2655798){#intref0010}PE/Cy7 anti-mouse CD279 (PD-1) Antibody (Clone RMP1-30)BioLegendCat\#109110; RRID: [AB_572017](nif-antibody:AB_572017){#intref0015}Ultra-LEAF Purified anti-human/mouse/rat CD278 (ICOS) antibody (Clone C398.4A)BioLegendCat\#313540; RRID: [AB_2687114](nif-antibody:AB_2687114){#intref0020}PE anti-mouse CD274 (B7-H1, PD-L1) antibody (Clone 10F.9G2)BioLegendCat\# 124307; RRID: [AB_2073557](nif-antibody:AB_2073557){#intref0025}BV421 Hamster Anti-Mouse CD183 Antibody (Clone CXCR3-173)BD BiosciencesCat\#562937; RRID: [AB_2687551](nif-antibody:AB_2687551){#intref0030}**Bacterial and Virus Strains**MSCV-UBC-GFP[@bib52]N/APIB-IRES-RFPThis paperN/APIB-IRES-EGFPThis paperN/AMSCV-LMP-AMT[@bib6]N/A**Chemicals, Peptides, and Recombinant Proteins**Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CFR&DCat\#Q9EP73Albumin from chicken egg whiteSigmaCat\#5503Lysozyme from hen egg whiteSigmaCat\#10837059001NP-KLH (Keyhole Limpet Hemocyanin)LGC Biosearch TechnologiesCat\#N-5060NP-OVAL (Ovalbumin)LGC Biosearch TechnologiesCat\#N-5051NP-PE (Phycoerythrin)LGC Biosearch TechnologiesCat\#N-5070NIP-BSA-BiotinLGC Biosearch TechnologiesCat\#N-1027**Critical Commercial Assays**Fixation/Permeabilization Solution KitBD BiosciencesCat\#554714Foxp3 / Transcription Factor Staining Buffer SeteBioscienceCat\#00-5523-00Ultra II DNA Library Prep Kit for IlluminaNEBCat\#E7645S**Deposited Data**Raw and analyzed dataThis paperGEO: [GSE112066](ncbi-geo:GSE112066){#intref0035}Mouse reference genome NCBI build 37.2, MGSCv37Genome Reference Consortium<https://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/mouse/>**Experimental Models: Cell Lines**Human: Platinum-E[@bib31]N/A**Experimental Models: Organisms/Strains**Mouse: *Pdcd1*^KI/KI^: C57BL/6- *Pdcd1*^KI/KI^[@bib51]N/AMouse: *Icos*^*−/−*^: B6.129P2-*Icos*^*tm1Mak*^/JThe Jackson LaboratoryJax 4859Mouse: *Icosl*^*−/−*^: B6.129P2-*Icosl*^*tm1Mak*^/JThe Jackson LaboratoryJax 4657Mouse: OT-II: B6.Cg-Tg(TcraTcrb)425Cbn/JThe Jackson LaboratoryJax 4194Mouse: MD4: C57BL/6-Tg(IghelMD4)4Ccg/JThe Jackson LaboratoryJax 2595Mouse: μMT: B6.129S2-*Ighm*^*tm1Cgn*^/JThe Jackson LaboratoryJax 2288Mouse: CD45.1: B6.SJL-*Ptprc*^*a*^*Pepc*^*b*^/BoyJThe Jackson LaboratoryJax 002014Mouse: *Sap*^−/−^: B6.129S6-*Sh2d1a*^*tm1Pls*^/J[@bib9]Jax 025754Mouse: dsRed: B6.Cg-Tg(CAG-DsRed^∗^MST)1Nagy/JThe Jackson LaboratoryJax 6051Mouse: *Cd274*^*−/−*^: C57BL/6- *Cd274*^*−/−*^This paperN/A**Oligonucleotides**VH186.2-1F: CTCTTCTTGGCAGCAACAGC[@bib27]N/AVH186.2-1R: GCTGCTCAGAGTGTAGAGGTC[@bib27]N/AVH186.2-2F: GTGTCCACTCCCAGGTCCAAC[@bib27]N/AVH186.2-2R: GTTCCAGGTCACTGTCACTG[@bib27]N/ACXCR3 shRNA-1: CTGCCTCAATCCGCTGCTCTATThis paperN/ACXCR3 shRNA-2: AGCCGATGTTCTGCTGGTGTTAThis paperN/ACd274 sgRNA: GTATGGCAGCAACGTCACGATGGThis paperN/ACd274 genotyping-F: TAACAGGTGATCCGTTTCCTATGThis paperN/ACd274 genotyping-F: CGTGATTCGCTTGTAGTCCGThis paperN/A**Recombinant DNA**MSCV-CXCR5-GFP[@bib52]N/APIB-PD-1-EGFPThis paperN/APIB-PD-1-RFPThis paperN/APIB-PD-1(Y225F) -RFPThis paperN/APIB-PD-1(Y248F) -RFPThis paperN/APIB-ICOS-RFPThis paperN/APIB-ICOS(Y181F) -RFPThis paperN/A**Software and Algorithms**TopHat2[@bib24]<http://ccb.jhu.edu/software/tophat>DESeq2[@bib28]<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Hai Qi (<qihai@mail.tsinghua.edu.cn>).

Experiment Model and Subject Details {#sec4.3}
------------------------------------

All mice were maintained under specific pathogen-free conditions and used in accordance of governmental and Tsinghua guidelines for animal welfare. Six- to 12-week-old, male and female, age and sex-matched mice were used for all experiments.

Platinum-E (Plat-E) Retroviral Packaging Cell Line was maintained in DMEM supplemented with 10% Fetal Bovine Serum, L-Glutamine, and penicillin/streptomycin. The cell line was female origin. Isolated CD4^+^ T cells were activated *in vitro* by plate-bound anti-CD3 (8μg/ml) and anti-CD28 (8μg/ml) and after 2 days pipetted off and cultured in RPMI-1640 supplemented with 10% Fetal Bovine Serum, L-Glutamine, Sodium Pyruvate, penicillin/streptomycin, 2-Mercaptoethanol and 10 ng/ml IL-2. All cultures were incubated in a humidified chamber at 5% CO~2~ and 37°C.

Method Details {#sec4.4}
--------------

### Animals and immunizations {#sec4.4.1}

B6 (Jax 664), CD45.1 (Jax 002014), μMT (Jax 2288), *Icos*^*−/−*^ (Jax 4859), *Icosl*^*−/−*^ (Jax 4657), dsRed-expressing (Jax 6051), T cell receptor transgenic OT-II mice (Jax 4194), and HEL-specific Ig-transgenic MD4 (Jax 2595) mice were from the Jackson Laboratory. *Pdcd1*^KI/KI^ mice were as previously described ([@bib51]). *Sh2d1a*^−/−^ (*Sap*^−/−^) mice were a kind gift from Dr. Pamela Schwartzberg ([@bib9]). Relevant mice were interbred to obtain *Pdcd1*^KI/KI^-OT-II, *Pdcd1*^KI/KI^-*Icos*^*−/−*^, dsRed-expressing MD4 mice.

To examine T cell distribution patterns in GCs, 3-5 × 10^5^ *in vitro* activated and retrovirally transduced OT-II T cells were intravenously transferred into B6 together with 5 × 10^5^ naive dsred-MD4 B cells before subcutaneous immunization with 130 μg HEL-OVA (Sigma) protein plus 0.5 μg LPS (Sigma) in alum (Thermo Scientific). To examine polyclonal GC responses with OT-II T cells as the helper, 5 × 10^5^ naive OT-II T cells were intravenously transferred into *Sap*^*−/−*^ hosts followed by immunization with 50 μg NP-OVA (Biosearch Technologies) plus 1μg LPS in alum intraperitoneally. To measure GC responses in mixed BM chimeras, mice were intraperitoneally immunized with 100 μg NP-KLH (Biosearch Technologies) plus 1 μg LPS in alum.

### Construction of bone marrow chimeras {#sec4.4.2}

B6 recipients were lethally irradiated by X-ray (5.5Gy × 2), and then intravenously transferred with a combination of 2-3 × 10^6^ bone-marrow leukocytes from indicated donors mixed at indicated ratios. Chimeras were used for experiments after 8-week reconstitution.

### Construction of *Cd274*^*−/−*^ mice {#sec4.4.3}

For germline ablation of the *Cd274* gene in B6 mice, the CRISPR/Cas9 technique was used. Briefly, guide RNA targeting an appropriate site on exon 3 and close to the ATG start codon was co-injected together with Cas9-coding mRNA. PCR-positive F0 mice were screened by Sanger sequencing of the genomic region targeted by the guide RNA. A line that showed a 17-bp deletion resulting in a frameshift and a premature stop codon was chosen to further validate at the level of protein expression (Figure S5). This line was backcrossed with B6 mice for at least 3 generations before use in subsequent experiments. The sgRNA sequence is GTATGGCAGCAACGTCACGATGG. The genotyping primers used are: (primer-F) 5′-TAACAGGTGATCCGTTTCCTATG and (primer-R) 5′-CGTGATTCGCTTGTAGTCCG.

### Retrovirus and *in vitro* transduction {#sec4.4.4}

Naive polyclonal T cells, OT-II T cells were isolated by CD4 Microbeads (Miltenyi Biotec) according to the manufacturer's protocols. CD4^+^ T cells were activated *in vitro* by plate-bound anti-CD3 (8μg/ml) and anti-CD28 (8μg/ml). Target genes were cloned into MSCV or PIB-based, GFP- or RFP-tagged retroviral vectors. Retroviruses were packaged with the Plat-E system. For transduction, 1-2 × 10^6^ T cells were typically spin-infected two times, one at 24 and the other at 48 h post activation, by 1,500 g centrifugation with desired viral supernatants containing 1 μg/ml polybrene (Sigma) and 10 ng/ml IL-2 (PeproTech) for 2 h at 32°C. Supernatants were then discarded and fresh media supplemented with10 ng/ml IL-2 were added. Transduced T cells were then cultured for another 3 days in complete media supplemented with 10 ng/ml IL-2 before sorting and transfer.

### Immunoblotting {#sec4.4.5}

Previously activated or retrovirally transduced T cells were deprived of serum for 3 h. Approximately 2 × 10^6^ T cells were suspended in serum-free RPMI-1640 medium, incubated with purified anti-ICOS (Biolegend) or CXCL13 (PeproTech) with or without PD-L1-Fc (R&D) of indicated concentration for 30 min in 37°C. Stimulated cells were quickly spun down and lysed by 2% SDS and loading buffer and then boiled at 100 °C for 15 min. Proteins were separated by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with TBS containing 5% milk and 0.1% Tween-20. Antibodies for immunoblotting included rabbit anti--pAKT (S473), anti-AKT, anti-actin, anti-pSHP-2 (Y542), anti-SHP2 (Cell Signaling Technology). Appropriate HRP-conjugated secondary reagents were from Jackson Immunoresearch Laboratories.

### Chemokine-stimulated T cell polarization assay {#sec4.4.6}

Activated T cells were retrovirally transduced with MSCV-CXCR5-GFP and PIB-PD-1-RFP. GFP^+^RFP^+^ co-transduced cells were sorted to \> 90% purity. After resting in complete RPMI-1640 media for 2-3 hours, cells were re-suspended to a density of 3 × 10^6^ cells/ml in the same media supplemented with or without 1 μg/ml recombinant CXCL13 (Peprotech) dropped onto L-Lysine-coated slides that were pre-incubated with PD-L1-hIgGFc or control human IgG. After incubation at 37°C for 30 min, cells were fixed with 1% paraformaldehyde and stained with AF568 Phalloidin (Invitrogen) to visualize F-actin. Slides were mounted with the ProlongGold Antifade reagent (Invitrogen) and examined with an Olympus FV1000 upright microscope using × 20 air immersion lens. Cells with an elongated shape (ratio of the cell length and width \> 1.5) are considered as polarized.

### Follicular homing assay and immunohistochemistry {#sec4.4.7}

Activated T cells were retrovirally transduced with MSCV-CXCR5-GFP alone or in combination with PIB-target gene-RFP. GFP^+^ or GFP^+^RFP^+^ cells were sorted to \> 90% purity and intravenously injected into B6 or desired hosts (2-3 × 10^6^ cells per mouse). 24 h later, splenic tissue blocks were fixed with 1% paraformaldehyde. Immunohistochemical staining was conducted to examine T cell distribution patterns according to protocols previously described ([@bib52]). Staining reagents included EF450 anti-CD3, EF660 anti-CD3, EF450 anti-IgD, AF647 anti-IgD (eBiosience), anti-GFP (ab6556, Abcam), AF488 donkey-anti-rabbit IgG (Invitrogen). Slides were mounted with the ProlongGold Antifade reagent (Invitrogen) and examined with an Olympus FV1000 upright microscope using × 20 air immersion lens. Care was to taken to exclude consecutive sections from the same lymph node or spleen to avoid under-sampling, and multiple animals from multiple independent experiments were always used for quantitating follicular homing coefficients. The representative images were pseudo-colored and output from Imaris (Bitplane).

### Flow cytometry {#sec4.4.8}

To phenotype distinct cell populations by flow cytometry, draining lymph node cells or splenocytes were washed with PBS, blocked with 20cμgcml^−1^ 2.4G2 (BioXcell), and then stained with indicated antibodies in MACS buffer (PBS supplemented with 1% FBS and 5cmM EDTA). Staining reagents included AF700 anti-CD4, APC-Cy7 anti-CD19, APC-Cy7 anti-B220, PerCP-Cy5.5 anti-IgD, APC anti-IgD, PE-Cy7 anti-CD95, BV510 anti-CD95, BV510 anti-CD138, AF647 anti-BCL6, APC-Cy7 anti-CD45.2, APC anti-CD45.2, PerCP-Cy5.5 anti-CD45.1, FITC anti-CD45.1, BV421 and-CXCR3, streptavidin-BV421 and PE anti-IgM^a^ from BD Biosciences; FITC anti-GL7, EF450 anti-GL7, AF700 anti-B220, FITC anti-IgD, streptavidin-PerCP-Cy5.5, streptavidin-PE, streptavidin-APC, PE anti-IL-21 and APC anti-IL-21 from eBioscience; APC anti-PD1, PE-Cy7 anti-PD1, biotinylated anti-ICOS, PE anti-ICOS and PE anti-CD40L from Biolegend; biotinylated anti-CXCR5 and PE anti-CXCR5 from Miltenyi. Isotype-matched control antibodies were purchased from these respective vendors. Surface staining was done on ice with primary reagents incubated for 30cminutes (90 minutes for CXCR5) followed by secondary reagents for 30cminutes with washes in-between. For intracellular staining of IL-21 or Bcl-6, the CytoFix/Perm kit (BD Biosciences) or the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) was respectively used according to manufacturers' protocols. To detect NP-binding cells, NP~(38)~- or NP~(44)~-PE were used. All cytometric data were collected on an LSR II or Aria III cytometer (BD Biosciences) and analyzed with the FlowJo software (TreeStar). Dead cells and non-singlet events were excluded from analyses based on staining of 7-amino-actinomycin D (7-AAD) (Biotium) or Zombie Yellow (Biolegend) and characteristics of forward- and side-scattering.

### V~H~186.2 sequence analysis of NP-specific GC B cells {#sec4.4.9}

To analyze V~H~ sequences of NP-specific GC B cell subsets, the antigen-binding cells pooled from 3-4 mice per group each experiment were identified by staining with biotinylated NIP~(15)~-BSA (Biosearch Technologies) at 330 ng/ml for 1 hours on ice and then with streptavidin APC. NIP-binding^+^GL7^+^FAS^+^CD19^+^ GC B cells were sorted 13 days after intraperitoneal NP-KLH immunization. After incubation at 60°C for 5 min in the lysis buffer, lysates of multiple 100-cell sorts per experiment was subjected to reverse-transcription by with the Superscript cDNA Synthesis Kit (Invitrogen) using the manufacturer's suggested protocol. V~H~186.2 fragments were amplified from the complementary DNA by nested PCR using the following primers (first sense: 5′-CTCTTCTTGGCAGCAACAGC, first antisense: 5′-GCTGCTCAGAGTGTAGAGGTC; second sense: 5′-GTGTCCACTCCCAGGTCCAAC, second antisense: 5′-GTTCCAGGTCACTGTCACTG). PCR products (400 base pairs) were purified by gel electrophoresis and cloned into a T vector (Takara), and individual bacterial colonies were picked for sequencing. Identical V~H~ sequences were counted only once as one clone, and the final result was compiled with unique clones for each category.

### CXCR3 knockdown {#sec4.4.10}

The mir-30 microRNA-based, Ametrine-tagged, shRNA-expressing MSCV-LMP vector was a kind gift from Dr. Yun-Cai Liu. Five CXCR3-targeting shRNA sequences were initially obtained from the CSHL website (<http://katahdin.cshl.org/homepage/siRNA/RNAi.cgi?type=shRNA>) and tested for the knockdown efficiency by surface staining of CD4^+^ T cells activated and transduced *in vitro*. Two highly efficient ones were used in subsequent experiments: (shRNA-1) CTGCCTCAATCCGCTGCTCTAT and (shRNA-2) AGCCGATGTTCTGCTGGTGTTA.

### RNA-seq {#sec4.4.11}

To conduct transcriptomic RNA-seq analyses on Tfh cells, we modified the protocol initially developed for single-cell RNA-seq to accommodate 200 sorted cells as previously described ([@bib48]). cDNAs were sheared by Covaris and subjected to Illumina TruSeq sequencing library preparation. All libraries were sequenced on a HiSeq 2500 sequencer (Illumina) in the SE-50 mode by Tsinghua core facility.

Quantification and Statistical Anaysis {#sec4.5}
--------------------------------------

For all relevant animal experiments, age- and sex-matched mice were randomly chosen to be in different treatment groups. Each group typically contained 3 to 5 animals, and 2 to 6 independent experiments were done for each assay. No blinding was involved in this work. Unless indicated otherwise, two-tailed t tests in Prism software (Graphpad) were used to compare endpoint means of different groups. Differences between groups were considered significant for p values \< 0.05.

For RNA-seq data analysis, after raw data were processed with CASAVA (Illumina) to generate fastq files, sequence reads were aligned to the *Mus musculus* reference genome using TopHat2. Taking into account only genes that have an average number of reads of at least 1, differential expression between any two cell subsets was calculated by the DESeq2 software (Bioconductor) with a call threshold set at *P*~adj~\<0.01. Two independent immunization experiments were conducted, and in each experiment spleens of 3 immunized mice were pooled to obtain three independent sorts of 200 cells for each Tfh genotype. As a result, for each Tfh genotype a total of 6 independent replicates were analyzed.

Data and Software Availability {#sec4.6}
------------------------------

RNA-seq data are deposited in GEO database under ID code [GSE112066](ncbi-geo:GSE112066){#interref0010}.

Supplemental Information {#app2}
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Document S1. Figures S1--S7Table S1. Differential Gene Expression between *Pdcd1*^KI/KI^ and WT Tfh Cells. Related to Figure 6GFP-transduced wildtype or *Pdcd1*^KI/KI^ OT-II T cells were transferred into B6 mice (5 × 10^5^ sorted GFP^+^ cells per mouse) together with 5 × 10^5^ dsRed-expressing MD4 B cells, and the recipients were subcutaneously immunized with HEL-OVA. CXCR5^hi^ OT-II T cells were sorted from the two groups on day 5 and subjected to transcriptomic analysis by RNA-seq. Differential gene expression result by DESeq2 is provided.Document S2. Article plus Supplemental Information
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